ProBioGen AG has signed a commercial license agreement with Roche to apply ProBioGen’s GlymaxX technology to boost the antibody’s ADCC anti-tumor activity.
 
The GlymaxX technology for production of afucosylated proteins is universally applicable, simple and potent. The advantage of the GlymaxX technology is that a single GlymaxX modified cell line is sufficient to produce both, completely fucosylated or afucosylated antibodies and those with an intermediate defined fuscosylation level. The technology can be integrated in newly developed or already existing cell lines of different origins.
 
ProBioGen specializes in developing and manufacturing complex therapeutic glycoproteins. The GlymaxX technology prevents the addition of the sugar “fucose” to the N-linked antibody carbohydrate part by antibody producing cells. The absence of fucose enhances ADCC (antibody-dependent cell-mediated cytotoxicity) activity for antibodies directed against cancer and infectious diseases.